Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Date of Report: August 12, 2021
Reporting Period: Quarter ended June 30, 2021
Status: Emerging Growth Company
This filing serves as a notification that the Company issued a press release on August 12, 2021, announcing its financial results for the quarter ended June 30, 2021. The full text of the press release is included as Exhibit 99.1.
Key Financial Metrics
The provided Form 8-K text acts as a cover document referencing the press release (Exhibit 99.1) but does not contain specific numerical data. Consequently, the following metrics are not available in this text:
- Revenue
- Profit/Loss
- Cash Flow
- Margins
- Debt and Liquidity
Note: The filing text does not provide a clear value for any financial metric.
Material Changes
The filing text does not detail specific material changes versus the prior comparable period. It only indicates that financial results for the quarter ended June 30, 2021, were announced.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These details are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual revenue, net loss, and cash position figures.
- Verify the Company's cash runway and burn rate based on the Q2 2021 results.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm if the "Emerging Growth Company" status impacts the disclosure of financial data.